Category Archives: by Brian Kelly

ISPOR Europe: Closing the gap between research and actionable outputs

Last month, thousands of global researchers, thought leaders and life sciences industry peers gathered in Italy for the 18th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). We were all there in the name of health economics and outcomes research, which is very appropriate given that health economics was first […]
Read More »

A look back at the ISPOR Annual International Meeting

Last week, participants from across our enterprise gathered in Philadelphia to contribute to the 20th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) conference. ISPOR advances the policy, science, and practice of pharmacoeconomics (or health economics) and outcomes research (the scientific discipline that evaluates the effect of health care interventions on patient well-being, including […]
Read More »

The Power of Real-World Evidence

Next week, May 16 – 20, Optum colleagues, clients, industry peers, global researchers and thought leaders are gathering in Philadelphia at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting. I’m looking forward to convening with our clients, discussing our progress and brainstorming about the new challenges to be tackled. Reflecting […]
Read More »

ISPOR Europe; A distinctive opportunity at the forefront of great change

In approximately 2 weeks, 3,800 global researchers and thought leaders will be coming together in Amsterdam to explore “New Challenges for Improving European Health Care” at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress, November 8-12. The conference is a great opportunity for us to interface with clients, partners and […]
Read More »

ISPOR, Optum and the Power of Real-World Data

The life sciences industry is facing unprecedented opportunities and challenges, and I’m excited. We’re entering new and diverse markets, unlike any we’ve experienced before, while at the same time the dynamics in existing markets are becoming more complex due to health care transformation efforts.